Inhaled Amikacin for Treatment of Refractory Pulmonary Nontuberculous Mycobacterial Disease

Abstract

In some patients with treatment-refractory pulmonary nontuberculous mycobacterial disease, the addition of inhaled amikacin was associated with microbiologic and/or symptomatic improvement; however, toxicity was common. Prospective evaluation of inhaled amikacin for mycobacterial disease is warranted.